ClinicalTrials.gg
CompletedNCT01098487Updated Mar 12, 2015Results posted

A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

A Phase 4 interventional study of Eltrombopag olamine in Purpura, Thrombocytopaenic, Idiopathic, sponsored by GlaxoSmithKline. Completed at 34 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-03-12.

Primary conditionPurpura, ThrombocytopenicRegistry: PurpuraReclassifiedWhy we changed it
Registry
Purpura — the first condition term the registry derived for this study.
ClinicalTrials.gg
Purpura, Thrombocytopenic
Why
  1. The study's title name Purpura, Thrombocytopenic, a narrower term within Purpura.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
167
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

A open-label, multi-center 2-year safety study to ascertain the baseline levels of bone marrow fibers in previously treated adults with chronic immune (idiopathic) thrombocytopenic purpura (ITP) and to evaluate the long-term effect of eltrombopag on bone marrow fibers. The study will also describe the long-term safety and tolerability of oral eltrombopag treatment in subjects with chronic ITP.

Read the detailed description

This is a phase IV, open-label safety study, designed to determine baseline levels of bone marrow fibers in previously treated adults with chronic immune (idiopathic) thrombocytopenic purpura (ITP)and to evaluate the long-term effect of eltrombopag on bone marrow reticulin and/or collagen fibers.

The duration of the screening period is up to 8 weeks. Eltrombopag will be administered for at least 2-years followed by a 4-week follow-up period. Bone marrow biopsies will be performed at screening, after 1-year and 2-years of eltrombopag treatment, and at early withdrawal of treatment. The screening bone marrow biopsy should be performed within 8 weeks of planned start of study medication and the bone marrow biopsy block must be available for central laboratory processing.

02

Conditions studied

  • Purpura, Thrombocytopaenic, Idiopathic

Browse trials for

Keywords

  • Immune (idiopathic) thrombocytopenic purpura (ITP)
  • bone marrow fibers
  • eltrombopag olamine
  • thrombopoietin receptor agonist
03

In context

Purpura, Thrombocytopenic Reclassified

32 studies on the registry are indexed under Purpura, Thrombocytopenic; 6 are open to participants now.

This study's enrollment of 167 is above the median of 54 across 22 interventional studies indexed under Purpura, Thrombocytopenic.

Browse Purpura, Thrombocytopenic studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Compared within Purpura, Thrombocytopenic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Purpura. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must have signed and dated a written and be able to understand and comply with protocol requirements and instructions.
  • Adults (≥18 years) diagnosed with chronic ITP according to the American Society for Hematology/British Committee for Standards in Hematology (ASH/BCSH) guidelines [George, 1996; BCSH, 2003; Provan, 2009]. In addition, a peripheral blood smear should support the diagnosis of ITP with no evidence of other disease causative of thrombocytopenia (e.g., pseudo thrombocytopenia, myelofibrosis). The physical examination should not suggest any disease, which may cause thrombocytopenia other than ITP.
  • Subjects must be physically eligible for serial bone marrow and must have a bone marrow biopsy performed during screening, and be willing to remain on the study for at least 2 years with annual bone marrow biopsies.
  • Subjects, who previously received eltrombopag or romiplostim, must have completed treatment with these therapies at least 6 months prior to the screening bone marrow biopsy.
  • Subjects must have the following clinical chemistry values:
  • and AST \< 2xULN;
  • \<1.5xULN (except for Gilbert's Syndrome);
  • Subjects are practicing an acceptable method of as specified in the protocol.
  • In France, subjects will be eligible for inclusion in this study, only if either affiliated to or a beneficiary of a social security category.

Exclusion criteria

Exclusion Criteria:

  • Subjects with any abnormality, other than ITP, or any other medical condition or circumstance, which in the opinion of the investigator makes the subject unsuitable for participation in the study or suggests another primary diagnosis (e.g., thrombocytopenia is secondary to another disease).
  • Subjects with any concurrent malignant disease and/or a recent history of cancer treatment with systemic chemotherapy and/or radiotherapy.

Exception: Subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.

  • Subjects with any prior history of arterial or venous thrombosis (stroke, , myocardial infarction, deep vein thrombosis or pulmonary embolism), AND ≥ two of the following risk factors: hormone replacement therapy, systemic (containing estrogen), smoking, diabetes, hypercholesterolemia, hypertension, cancer, hereditary thrombophilic disorders (e.g., Factor V Leiden, ATIII deficiency, etc), or any family history of arterial or venous thrombosis.
  • Subjects with screening bone marrow fibers of either MF Grade 3 using European Consensus scale or Grade 4 using Bauermeister scale.
  • Subjects with a >450 msec or > 480 msec for subjects with Bundle Branch Block.
  • Female subjects who are nursing or pregnant (positive serum or urine β-human chorionic gonadotrophin (β-hCG) pregnancy test) at screening.
  • Subjects treated with an drug (other than a thrombopopoetin-receptor (TPO-R) agonist) within 30 days or five half-lives (whichever is longer) preceding the first dose of eltrombopag in the study. (For romiplostim or eltrombopag, see inclusion criterion #4).
  • Subjects treated with any TPO-R agonist other than romiplostim or eltrombopag.
  • Subjects with recent history of alcohol/drug abuse as determined by the investigator.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
167 participants (actual)

Study arms

  • Experimental
    Open Label

    Oral eltrombopag once daily, starting dose 50 mg (or 25 mg for subjects of East Asian ancestry).

    Drug: Eltrombopag olamine

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Bone Marrow (BM) Fibers of MF Grade 0, 1, 2 and 3 on the European Consensus (EC) Scale at Baseline

    The evaluation of fibrosis was performed using BM biopsies in which the amount of fibrosis was assessed by the EC Grading Scale. This method distinguishes four degrees of fibrosis (myelofibrosis \[MF\]-0 to MF-3). MF Grade (G) 0 is scattered linear reticulin with no intersections (cross-overs) corresponding to normal BM; MF Grade 1 is loose network of reticulin with many intersections, especially in perivascular areas; MF Grade 2 is diffuse and dense increase in reticulin with extensive intersections, occasionally with only focal bundles of collagen and/or focal osteosclerosis; MF Grade 3 is diffuse and dense increase in reticulin with extensive intersections with coarse bundles of collagen, often associated with significant osteosclerosis. Baseline is defined as the most recent centrally-reviewed BM biopsy prior to first dose of eltrombopag in the study.

    Time frame: Baseline

  2. Number of Participants With a Positive or Negative Collagen Level at Baseline

    The number of participants with a positive or negative collagen level was analyzed. Baseline is defined as the most recent centrally-reviewed BM biopsy prior to first dose of eltrombopag in the study.

    Time frame: Baseline

  3. Number of Participants With Indicated Grade Change From Baseline in the EC Grading Scale at 1 Year

    The change from baseline to on-treatment assessments of European Consensus (EC) scale was analyzed. On-treatment is defined as during the treatment period (including dose interruptions) and up to 14 days after the end of the treatment period. MF-0 is scattered linear reticulin with no intersections (cross-overs) corresponding to normal BM; MF-1 is loose network of reticulin with many intersections, especially in perivascular areas; MF-2 is diffuse and dense increase in reticulin with extensive intersections, occasionally with only focal bundles of collagen and/or focal osteosclerosis; MF-3 is diffuse and dense increase in reticulin with extensive intersections with coarse bundles of collagen, often associated with significant osteosclerosis. Baseline is defined as the most recent centrally-reviewed BM biopsy prior to first dose of eltrombopag in the study.

    Time frame: Baseline and 1 year

  4. Number of Participants With Indicated Change From Baseline in the EC Grading Scale at 2 Years

    The change from baseline to on-treatment assessments of European Consensus (EC) scale was analyzed. On-treatment is defined as during the treatment period (including dose interruptions) and up to 14 days after the end of the treatment period. MF-0 is scattered linear reticulin with no intersections (cross-overs) corresponding to normal BM; MF-1 is loose network of reticulin with many intersections, especially in perivascular areas; MF-2 is diffuse and dense increase in reticulin with extensive intersections, occasionally with only focal bundles of collagen and/or focal osteosclerosis; MF-3 is diffuse and dense increase in reticulin with extensive intersections with coarse bundles of collagen, often associated with significant osteosclerosis. Baseline is defined as the most recent centrally-reviewed BM biopsy prior to first dose of eltrombopag in the study.

    Time frame: Baseline and 2 years

  5. Number of Participants With a Positive or Negative Collagen Level at 1 Year

    The change from Baseline to on-treatment assessments of collagen level was analyzed. On-treatment is defined as during the treatment period (including dose interruptions) and up to 14 days after the end of the treatment period.

    Time frame: 1 year

  6. Number of Participants With a Positive or Negative Collagen Level at 2 Year

    The change from Baseline to on-treatment assessments of collagen level was analyzed. On-treatment is defined as during the treatment period (including dose interruptions) and up to 14 days after the end of the treatment period.

    Time frame: 2 years

Secondary outcomes

  1. Number of Participants With the Indicated Maximum Toxicity Grade for the Indicated Clinical Chemistry Parameters at Any Time Post-Baseline During the Study

    Clinical chemistry parameters were summarized according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0: G0, none; G1, mild; G2, moderate; G3, severe; G4, life-threatening or disabling. Clinical chemistry parameters included: albumin, alkaline phosphatase (ALP), alanine amino transferase (ALT), aspartate amino transferase (AST), total bilirubin, calcium (hypercalcemia), calcium (hypocalcemia), potassium (hyperkalemia), potassium (hypokalemia), sodium (hypernatremia), sodium (hyponatremia), inorganic phosphorus and creatinine. Baseline values were obtained at Day 1. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). The maximum post-Baseline toxicity grade includes any scheduled or unscheduled post-Baseline assessment during.

    Time frame: From Week 1 up to Week 104 and up to 6 months follow-up (4 weeks for most participants) (up to approximately 2.5 years)

  2. Number of Participants With the Indicated Maximum Toxicity Grade for the Indicated Hematology Parameters at Any Time Post-Baseline During the Study

    Hematology parameters were summarized according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0: G0, none; G1, mild; G2, moderate; G3, severe; G4, life-threatening or disabling. Hematology parameters included: hemoglobin (increased), hemoglobin (anemia), lymphocyte count (increased), lymphocyte count (decreased), total absolute neutrophil count (ANC), platelet count and white blood cell (WBC) count. Baseline values were obtained at Day 1. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). The maximum post-Baseline toxicity grade includes any scheduled or unscheduled post-Baseline assessment during.

    Time frame: From Week 1 up to Week 104 and up to 6 months follow-up (4 weeks for most participants) (up to approximately 2.5 years)

  3. Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) Started On-therapy + 1 Day, >1 to 30 Days Post Therapy and >30 Days Post Therapy

    On-therapy + 1 day is defined as AEs started between the first dose of eltrombopag and up to the day after the last dose of eltrombopag; \>1 to 30 days post therapy is defined as AEs that started more than 1 day and up to 30 days after the last dose of eltrombopag; \>30 days post therapy is defined as AEs started that started more than 30 days after the last dose of eltrombopag. An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, or is a congenital anomaly or birth defect. Medical or scientific judgment should be exercised in other situations.

    Time frame: From Week 1 up to Week 104 and up to 6 months follow-up (4 weeks for most participants) (up to approximately 2.5 years)

07

Results

Posted Mar 12, 2015

Participant flow

Participant flow — Overall Study
MilestoneEltrombopag
Started162
Completed118
Not completed44
Withdrew: Adverse event22
Withdrew: Lack of efficacy11
Withdrew: Withdrawal by subject7
Withdrew: Lost to follow-up3
Withdrew: Physician decision1

Outcome measures

PrimaryNumber of Participants With Bone Marrow (BM) Fibers of MF Grade 0, 1, 2 and 3 on the European Consensus (EC) Scale at Baseline

The evaluation of fibrosis was performed using BM biopsies in which the amount of fibrosis was assessed by the EC Grading Scale. This method distinguishes four degrees of fibrosis (myelofibrosis \[MF\]-0 to MF-3). MF Grade (G) 0 is scattered linear reticulin with no intersections (cross-overs) corresponding to normal BM; MF Grade 1 is loose network of reticulin with many intersections, especially in perivascular areas; MF Grade 2 is diffuse and dense increase in reticulin with extensive intersections, occasionally with only focal bundles of collagen and/or focal osteosclerosis; MF Grade 3 is diffuse and dense increase in reticulin with extensive intersections with coarse bundles of collagen, often associated with significant osteosclerosis. Baseline is defined as the most recent centrally-reviewed BM biopsy prior to first dose of eltrombopag in the study.

Time frame:
Baseline
Reported as:
Number · Participants
Number of Participants With Bone Marrow (BM) Fibers of MF Grade 0, 1, 2 and 3 on the European Consensus (EC) Scale at Baseline
ParticipantsEltrombopag
MF-0150
MF-19
MF-20
MF-30
PrimaryNumber of Participants With a Positive or Negative Collagen Level at Baseline

The number of participants with a positive or negative collagen level was analyzed. Baseline is defined as the most recent centrally-reviewed BM biopsy prior to first dose of eltrombopag in the study.

Time frame:
Baseline
Reported as:
Number · Participants
Number of Participants With a Positive or Negative Collagen Level at Baseline
ParticipantsEltrombopag
Negative159
Positive0
PrimaryNumber of Participants With Indicated Grade Change From Baseline in the EC Grading Scale at 1 Year

The change from baseline to on-treatment assessments of European Consensus (EC) scale was analyzed. On-treatment is defined as during the treatment period (including dose interruptions) and up to 14 days after the end of the treatment period. MF-0 is scattered linear reticulin with no intersections (cross-overs) corresponding to normal BM; MF-1 is loose network of reticulin with many intersections, especially in perivascular areas; MF-2 is diffuse and dense increase in reticulin with extensive intersections, occasionally with only focal bundles of collagen and/or focal osteosclerosis; MF-3 is diffuse and dense increase in reticulin with extensive intersections with coarse bundles of collagen, often associated with significant osteosclerosis. Baseline is defined as the most recent centrally-reviewed BM biopsy prior to first dose of eltrombopag in the study.

Time frame:
Baseline and 1 year
Reported as:
Number · Participants
Number of Participants With Indicated Grade Change From Baseline in the EC Grading Scale at 1 Year
ParticipantsEltrombopag
MF-0 to MF-082
MF-0 to MF-133
MF-0 to MF-22
MF-0 to MF-32
MF-1 to MF-03
MF-1 to MF-12
MF-1 to MF-21
MF-1 to MF-30
MF-2 to MF-00
MF-2 to MF-10
MF-2 to MF-20
MF-2 to MF-30
MF-3 to MF-00
MF-3 to MF-10
MF-3 to MF-20
MF-3 to MF-30
Missing to MF-02
Missing to MF-10
Missing to MF-20
Missing to MF-30
PrimaryNumber of Participants With Indicated Change From Baseline in the EC Grading Scale at 2 Years

The change from baseline to on-treatment assessments of European Consensus (EC) scale was analyzed. On-treatment is defined as during the treatment period (including dose interruptions) and up to 14 days after the end of the treatment period. MF-0 is scattered linear reticulin with no intersections (cross-overs) corresponding to normal BM; MF-1 is loose network of reticulin with many intersections, especially in perivascular areas; MF-2 is diffuse and dense increase in reticulin with extensive intersections, occasionally with only focal bundles of collagen and/or focal osteosclerosis; MF-3 is diffuse and dense increase in reticulin with extensive intersections with coarse bundles of collagen, often associated with significant osteosclerosis. Baseline is defined as the most recent centrally-reviewed BM biopsy prior to first dose of eltrombopag in the study.

Time frame:
Baseline and 2 years
Reported as:
Number · Participants
Number of Participants With Indicated Change From Baseline in the EC Grading Scale at 2 Years
ParticipantsEltrombopag
MF-0 to MF-079
MF-0 to MF-19
MF-0 to MF-20
MF-0 to MF-30
MF-1 to MF-02
MF-1 to MF-11
MF-1 to MF-20
MF-1 to MF-30
MF-2 to MF-00
MF-2 to MF-10
MF-2 to MF-20
MF-2 to MF-30
MF-3 to MF-00
MF-3 to MF-10
MF-3 to MF-20
MF-3 to MF-30
Missing to MF-02
Missing to MF-10
Missing to MF-20
Missing to MF-30
PrimaryNumber of Participants With a Positive or Negative Collagen Level at 1 Year

The change from Baseline to on-treatment assessments of collagen level was analyzed. On-treatment is defined as during the treatment period (including dose interruptions) and up to 14 days after the end of the treatment period.

Time frame:
1 year
Reported as:
Number · Participants
Number of Participants With a Positive or Negative Collagen Level at 1 Year
ParticipantsEltrombopag
Negative to Negative120
Negative to Positive5
Positive to Negative0
Positive to Positive0
Missing to Negative2
Missing to Positive0
PrimaryNumber of Participants With a Positive or Negative Collagen Level at 2 Year

The change from Baseline to on-treatment assessments of collagen level was analyzed. On-treatment is defined as during the treatment period (including dose interruptions) and up to 14 days after the end of the treatment period.

Time frame:
2 years
Reported as:
Number · Participants
Number of Participants With a Positive or Negative Collagen Level at 2 Year
ParticipantsEltrombopag
Negative to Negative90
Negative to Positive1
Positive to Negative0
Positive to Positive0
Missing to Negative2
Missing to Positive0
SecondaryNumber of Participants With the Indicated Maximum Toxicity Grade for the Indicated Clinical Chemistry Parameters at Any Time Post-Baseline During the Study

Clinical chemistry parameters were summarized according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0: G0, none; G1, mild; G2, moderate; G3, severe; G4, life-threatening or disabling. Clinical chemistry parameters included: albumin, alkaline phosphatase (ALP), alanine amino transferase (ALT), aspartate amino transferase (AST), total bilirubin, calcium (hypercalcemia), calcium (hypocalcemia), potassium (hyperkalemia), potassium (hypokalemia), sodium (hypernatremia), sodium (hyponatremia), inorganic phosphorus and creatinine. Baseline values were obtained at Day 1. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). The maximum post-Baseline toxicity grade includes any scheduled or unscheduled post-Baseline assessment during.

Time frame:
From Week 1 up to Week 104 and up to 6 months follow-up (4 weeks for most participants) (up to approximately 2.5 years)
Reported as:
Number · Participants
Number of Participants With the Indicated Maximum Toxicity Grade for the Indicated Clinical Chemistry Parameters at Any Time Post-Baseline During the Study
ParticipantsEltrombopag
Albumin, G0, n=162151
Albumin, G1, n=1625
Albumin, G2, n=1626
Albumin, G3, n=1620
Albumin, G4, n=1620
ALP, G0, n=162125
ALP, G1, n=16235
ALP, G2, n=1622
ALP, G3, n=1620
ALP, G4, n=1620
ALT, G0, n=162109
ALT, G1, n=16237
ALT, G2, n=1628
ALT, G3, n=1627
ALT, G4, n=1621
AST, G0, n=16299
AST, G1, n=16248
AST, G2, n=1628
AST, G3, n=1625
AST, G4, n=1622
Total bilirubin, G0, n=162103
Total bilirubin, G1, n=16240
Total bilirubin, G2, n=16217
Total bilirubin, G3, n=1622
Total bilirubin, G4, n=1620
Calcium (hypercalcemia), G0, n=162159
Calcium (hypercalcemia), G1, n=1622
Calcium (hypercalcemia), G2, n=1621
Calcium (hypercalcemia), G3, n=1620
Calcium (hypercalcemia), G4, n=1620
Calcium (hypocalcemia), G0, n=16292
Calcium (hypocalcemia), G1, n=16257
Calcium (hypocalcemia), G2, n=16212
Calcium (hypocalcemia), G3, n=1620
Calcium (hypocalcemia), G4, n=1621
Potassium (hyperkalemia), G0, n=162138
Potassium (hyperkalemia), G1, n=16214
Potassium (hyperkalemia), G2, n=1625
Potassium (hyperkalemia), G3, n=1625
Potassium (hyperkalemia), G4, n=1620
Potassium (hypokalemia), G0, n=162123
Potassium (hypokalemia), G1, n=16235
Potassium (hypokalemia), G2, n=1620
Potassium (hypokalemia), G3, n=1624
Potassium (hypokalemia), G4, n=1620
Sodium (hypernatremia), G0, n=162138
Sodium (hypernatremia), G1, n=16220
Sodium (hypernatremia), G2, n=1622
Sodium (hypernatremia), G3, n=1622
Sodium (hypernatremia), G4, n=1620
Sodium (hyponatremia), G0, n=162137
Sodium (hyponatremia), G1, n=16221
Sodium (hyponatremia), G2, n=1620
Sodium (hyponatremia), G3, n=1623
Sodium (hyponatremia), G4, n=1621
Inorganic phosphorus, G0, n=162100
Inorganic phosphorus, G1, n=1620
Inorganic phosphorus, G2, n=16252
Inorganic phosphorus, G3, n=16210
Inorganic phosphorus, G4, n=1620
Creatinine, G0, n=162149
Creatinine, G1, n=1628
Creatinine, G2, n=1623
Creatinine, G3, n=1620
Creatinine, G4, n=1622
SecondaryNumber of Participants With the Indicated Maximum Toxicity Grade for the Indicated Hematology Parameters at Any Time Post-Baseline During the Study

Hematology parameters were summarized according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0: G0, none; G1, mild; G2, moderate; G3, severe; G4, life-threatening or disabling. Hematology parameters included: hemoglobin (increased), hemoglobin (anemia), lymphocyte count (increased), lymphocyte count (decreased), total absolute neutrophil count (ANC), platelet count and white blood cell (WBC) count. Baseline values were obtained at Day 1. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). The maximum post-Baseline toxicity grade includes any scheduled or unscheduled post-Baseline assessment during.

Time frame:
From Week 1 up to Week 104 and up to 6 months follow-up (4 weeks for most participants) (up to approximately 2.5 years)
Reported as:
Number · Participants
Number of Participants With the Indicated Maximum Toxicity Grade for the Indicated Hematology Parameters at Any Time Post-Baseline During the Study
ParticipantsEltrombopag
Hemoglobin (increased), G0, n=162143
Hemoglobin (increased), G1, n=16217
Hemoglobin (increased), G2, n=1621
Hemoglobin (increased), G3, n=1621
Hemoglobin (increased), G4, n=1620
Hemoglobin (anemia), G0, n=16255
Hemoglobin (anemia), G1, n=16263
Hemoglobin (anemia), G2, n=16231
Hemoglobin (anemia), G3, n=16213
Hemoglobin (anemia), G4, n=1620
Lymphocyte count (increased), G0, n=161122
Lymphocyte count (increased), G1, n=1610
Lymphocyte count (increased), G2, n=16139
Lymphocyte count (increased), G3, n=1610
Lymphocyte count (increased), G4, n=1610
Lymphocyte count (decreased), G0, n=16186
Lymphocyte count (decreased), G1, n=16136
Lymphocyte count (decreased), G2, n=16126
Lymphocyte count (decreased), G3, n=16113
Lymphocyte count (decreased), G4, n=1610
Total ANC, G0, n=161140
Total ANC, G1, n=16112
Total ANC, G2, n=1613
Total ANC, G3, n=1613
Total ANC, G4, n=1613
Platelet count, G0, n=1622
Platelet count, G1, n=1628
Platelet count, G2, n=1623
Platelet count, G3, n=16226
Platelet count, G4, n=162123
WBC, G0, n=162135
WBC, G1, n=16221
WBC, G2, n=1623
WBC, G3, n=1623
WBC, G4, n=1620
SecondaryNumber of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) Started On-therapy + 1 Day, >1 to 30 Days Post Therapy and >30 Days Post Therapy

On-therapy + 1 day is defined as AEs started between the first dose of eltrombopag and up to the day after the last dose of eltrombopag; \>1 to 30 days post therapy is defined as AEs that started more than 1 day and up to 30 days after the last dose of eltrombopag; \>30 days post therapy is defined as AEs started that started more than 30 days after the last dose of eltrombopag. An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, or is a congenital anomaly or birth defect. Medical or scientific judgment should be exercised in other situations.

Time frame:
From Week 1 up to Week 104 and up to 6 months follow-up (4 weeks for most participants) (up to approximately 2.5 years)
Reported as:
Number · Participants
Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) Started On-therapy + 1 Day, >1 to 30 Days Post Therapy and >30 Days Post Therapy
ParticipantsEltrombopag
Any AE, on-therapy + 1 day141
Any SAE, on-therapy + 1 day41
Any AE, >1 to 30 days post therapy12
Any SAE, >1 to 30 days post therapy5
Any AE, >30 days post therapy9
Any SAE, >30 days post therapy1

Adverse events

Collected over On-treatment SAEs and non-serious AEs are defined as events occuring from the start of the treatment (Day 1) up to Week 104 and including the follow-up period of up to 6 months (only 4 weeks for most participants) (up to approximately 2.5 years).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eltrombopag—42/162 (25.9%)114/162 (70.4%)
Most frequent serious events
Showing 10 of 63
Most frequent serious events
EventEltrombopag
Gastrointestinal haemorrhageGastrointestinal disorders3/162
MenorrhagiaReproductive system and breast disorders3/162
AnaemiaBlood and lymphatic system disorders2/162
ThrombocytopeniaBlood and lymphatic system disorders2/162
VertigoEar and labyrinth disorders2/162
Gingival bleedingGastrointestinal disorders2/162
NauseaGastrointestinal disorders2/162
VomitingGastrointestinal disorders2/162
FatigueGeneral disorders2/162
Tooth abscessInfections and infestations2/162
Most frequent other events
Showing 10 of 36
Most frequent other events
EventEltrombopag
HeadacheNervous system disorders30/162
CoughRespiratory, thoracic and mediastinal disorders24/162
ArthralgiaMusculoskeletal and connective tissue disorders22/162
DiarrhoeaGastrointestinal disorders21/162
NauseaGastrointestinal disorders21/162
Upper respiratory tract infectionInfections and infestations20/162
PyrexiaGeneral disorders18/162
NasopharyngitisInfections and infestations17/162
Back painMusculoskeletal and connective tissue disorders17/162
PetechiaeSkin and subcutaneous tissue disorders17/162

Baseline characteristics

All Treated Subjects (ATS) Population: all participants who received at least one dose of study medication excluding the 5 participants from Center 082877.

Age, Continuous
Age, Continuous(Years)Eltrombopag
Mean43.1 ± 16.31
Sex: Female, Male
Sex: Female, Male(Participants)Eltrombopag
Female104
Male58
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Eltrombopag
Asian - Central/South Asian Heritage47
Asian - East Asian Heritage32
Asian - South East Asian Heritage1
White - White/Caucasian/European Heritage81
Missing1
08

Study locations

34 sites
  • GSK Investigational Site
    New York, New York 10021, United States
  • GSK Investigational Site
    Hradec Kralove, Czech Republic
  • GSK Investigational Site
    Olomouc, 775 20, Czech Republic
  • GSK Investigational Site
    Praha 2, 128 08, Czech Republic
  • GSK Investigational Site
    Caen cedex 9, 14033, France
  • GSK Investigational Site
    Créteil, 94010, France
  • GSK Investigational Site
    Pessac Cedex, 33604, France
  • GSK Investigational Site
    Muenchen, Bayern 81241, Germany
  • GSK Investigational Site
    Muenchen, Bayern 81377, Germany
  • GSK Investigational Site
    Duesseldorf, Nordrhein-Westfalen 40225, Germany
  • GSK Investigational Site
    Duesseldorf, Nordrhein-Westfalen 40479, Germany
  • GSK Investigational Site
    Essen, Nordrhein-Westfalen 45122, Germany
  • GSK Investigational Site
    Berlin, 13353, Germany
  • GSK Investigational Site
    Shatin, New Territories, Hong Kong
  • GSK Investigational Site
    Debrecen, 4012, Hungary
  • GSK Investigational Site
    Győr, 9023, Hungary
  • GSK Investigational Site
    Szeged, 6720, Hungary
  • GSK Investigational Site
    Ludhiana, 141008, India
  • GSK Investigational Site
    Pune, 411004, India
  • GSK Investigational Site
    Surat, 395002, India
  • GSK Investigational Site
    Vellore, 632004, India
  • GSK Investigational Site
    Bologna, Emilia-Romagna 40138, Italy
  • GSK Investigational Site
    Milano, Lombardia 20132, Italy
  • GSK Investigational Site
    Milano, Lombardia 20162, Italy
  • GSK Investigational Site
    Padova, Veneto 35128, Italy
  • GSK Investigational Site
    Vicenza, Veneto 36100, Italy
  • GSK Investigational Site
    Seongnam-si Gyeonggi-do, 463-712, Korea, Republic of
  • GSK Investigational Site
    Seoul, 135-710, Korea, Republic of
  • GSK Investigational Site
    Seoul, 137-701, Korea, Republic of
  • GSK Investigational Site
    Karachi, 75300, Pakistan
  • GSK Investigational Site
    Lahore, 54600, Pakistan
  • GSK Investigational Site
    Moscow, 125167, Russian Federation
  • GSK Investigational Site
    Novosibirsk, 630087, Russian Federation
  • GSK Investigational Site
    St Petersburg, 193024, Russian Federation
09

References and documents

Publications

  • Wong RS, Bakshi K, Brainsky A. Thrombophilia in patients with chronic immune thrombocytopenia. Scand J Clin Lab Invest. 2015 Jan;75(1):13-7. doi: 10.3109/00365513.2014.962597. Epub 2014 Oct 9. PubMed 25296772 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2010, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2015, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2010
First posted
Apr 2, 2010
Start
May 2010
Primary completionActual
May 2014
CompletionActual
May 2014
Results first posted
Mar 12, 2015
Last update
Mar 12, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01098487
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 2, 2010
Start date
May 2010
Primary completion
May 2014
Completion
May 2014
Results posted
Mar 12, 2015
Last update
Mar 12, 2015

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrombopag

Start the discussion